Officials say they’re scrambling to respond to an uncharacteristic surge in RSV, a common respiratory illness that’s filling up pediatric hospital beds nationwide:
, most of us get it by the age of 2. The symptoms look like a cold and most people recover unscathed in a week or two. But it can be serious for infants, adults over 65 and others with weakened immune systems. While elderly adults are the most at risk of dying from RSV, it’s also the leading cause of bronchiolitis and pneumonia for those under the age of 1, according to the CDC.
, as most but not all COVID precautions were dropped. As children return to schools and daycares this fall after two years of mostly masked or remote schooling, health experts say a lot of them — especially the youngest cohort — are getting exposed to the virus for the first time. According to the CDC, the RSV rate in Massachusetts has more than quadrupled since early September.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Rising RSV respiratory virus hits kids hard, fills pediatric wards in Greater ClevelandUH Rainbow and Children’s Hospital is seeing double the number of children with RSV in their emergency department, compared with a month ago. And MetroHealth has seen a 500% increase in the past month.
Consulte Mais informação »
DC-Area Parents Struggle To Navigate Pediatric RSV SurgeLocal parents share their experiences navigating an RSV surge amidst pediatric bed shortages and the possibility of reduced immunity in children as pandemic protections wane.
Consulte Mais informação »
New RSV vaccine given in pregnancy protects newborns from illness, Pfizer saysThe drugmaker Pfizer announced positive trial results for its RSV vaccine designed to protect newborns.
Consulte Mais informação »
Colorado’s RSV hospitalizations already above last year’s peak as children’s hospitals brace for worseColorado children’s hospitals, which were largely spared the worst of COVID-19, are now facing their own crush of patients as respiratory syncytial virus and other common bugs return — and the poss…
Consulte Mais informação »
‘Extremely satisfying’: Scientist’s insight powers new RSV vaccine for infantsAmid the surge of respiratory syncytial virus, Barney Graham—a former scientist at the U.S. National Institute of Allergy and Infectious Diseases—reflects on how his team’s work was key to the apparent success of Pfizer’s RSV vaccine and others.
Consulte Mais informação »